Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

References

• Menter, A., Gottlieb, A., Feldman, S.R., Van Voorhees, A.S., Leonardi, C.L., Gordon, K.B., Lebwohl, M., Koo, J.Y., Elmets, C.A., Korman, N.J., Beutner, K.R., Bhushan, R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008, 58, 826–850.
   PubMed Web of Science ®Google Scholar
• Gottlieb, A., Korman, N.J., Gordon, K.B., Feldman, S.R., Lebwohl, M., Koo, J.Y., Van Voorhees, A.S., Elmets, C.A., Leonardi, C.L., Beutner, K.R., Bhushan, R., Menter, A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58, 851–864.
   PubMed Web of Science ®Google Scholar
• Davidovici, B.B., Sattar, N., Prinz, J.C., Jörg, P.C., Puig, L., Emery, P., Barker, J.N., van de Kerkhof, P., Ståhle, M., Nestle, F.O., Girolomoni, G., Krueger, J.G. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010, 130, 1785–1796.
   PubMed Web of Science ®Google Scholar
• Gisondi, P., Girolomoni, G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009, 35, 313–324.
   PubMed Web of Science ®Google Scholar
• Finlay, A.Y. Current severe psoriasis and the rule of tens. Br J Dermatol 2005, 152, 861–867.
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration–Australian Government’s Department of Health and Ageing. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis [online]. [cited 2010 December 15]; Available from: http://www.tga.gov.au/docs/pdf/euguide/ewp/245402en.pdf.
   Google Scholar
• Gisondi, P., Girolomoni, G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007, 6, 515–519.
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio, L., Van Voorhees, A.S. Long-term efficacy of biologics in dermatology. Dermatol Ther 2009, 22, 22–33.
   PubMedGoogle Scholar
• Gladman, D.D. Psoriatic arthritis. Dermatol Ther 2009, 22, 40–55.
   PubMed Web of Science ®Google Scholar
• Weger, W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010, 160, 810–820.
   PubMed Web of Science ®Google Scholar
• Fantuzzi, F., Del Giglio, M., Gisondi, P., Girolomoni, G. Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008, 12, 1085–1096.
   PubMed Web of Science ®Google Scholar
• Miller, D.W., Feldman, S.R. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 2006, 7, 157–167.
   PubMed Web of Science ®Google Scholar
• Chaudhari, U., Romano, P., Mulcahy, L.D., Dooley, L.T., Baker, D.G., Gottlieb, A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357, 1842–1847.
   PubMed Web of Science ®Google Scholar
• Langley, R.G., Strober, B.E., Gu, Y., Rozzo, S.J., Okun, M.M. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010, 162, 1349–1358.
   PubMed Web of Science ®Google Scholar
• Ravindran, V., Scott, D.L., Choy, E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008, 67, 855–859.
   PubMed Web of Science ®Google Scholar
• Kircik, L.H., Del Rosso, J.Q. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009, 8, 546–559.
   PubMed Web of Science ®Google Scholar
• Korkina, L., Trakhtman, P., De Luca, C., Leoni, L., Raskovic, D., Pastore, S. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks? Drugs Today 2010, 46, 119–136.
   PubMed Web of Science ®Google Scholar
• Sfikakis, P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11, 180–210.
   PubMedGoogle Scholar
• Rawlins, M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008, 372, 2152–2161.
   PubMed Web of Science ®Google Scholar
• Silverman, S.L. From randomized controlled trials to observational studies. Am J Med 2009, 122, 114–120.
   PubMed Web of Science ®Google Scholar
• Albrecht, J., Werth, V.P., Bigby, M. The role of case reports in evidence-based practice, with suggestions for improving their reporting. J Am Acad Dermatol 2009, 60, 412–418.
   PubMedGoogle Scholar
• Gomez-Reino, J.J., Carmona, L.; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8, R29.
   PubMed Web of Science ®Google Scholar
• Saad, A.A., Ashcroft, D.M., Watson, K.D., Hyrich, K.L., Noyce, P.R., Symmons, D.P.; British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009, 11, R52.
   PubMed Web of Science ®Google Scholar
• Glintborg, B., Østergaard, M., Dreyer, L., Krogh, N.S., Tarp, U., Hansen, M.S., Rifbjerg-Madsen, S., Lorenzen, T., Hetland, M.L. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63, 382–390.
   PubMed Web of Science ®Google Scholar
• Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., Dougados, M. Infections during tumour necrosis factor- α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007, 46, 327–334.
   PubMed Web of Science ®Google Scholar
• Askling, J., Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20, 138–144.
   PubMed Web of Science ®Google Scholar
• Dixon, W.G., Watson, K., Lunt, M., Hyrich, K.L., Silman, A.J., Symmons, D.P.; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54, 2368–2376.
   PubMed Web of Science ®Google Scholar
• Dixon, W., Hyrich, K.L., Watson, K., Lunt, M.. The influence of anti-TNF therapy upon the incidence and severity of serious lower respirtory tract infections in patients with rheumatoid arthritis: results from the BSR biologics register (BSRBR) [abstract no. 157]. Rheumatology (Oxford) 2008;47:ii47.
   PubMedGoogle Scholar
• Carmona, L., Gómez-Reino, J.J.; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8, R72.
   PubMed Web of Science ®Google Scholar
• Grijalva, C.G., Chen, L., Delzell, E., Baddley, J.W., Beukelman, T., Winthrop, K.L., Griffin, M.R., Herrinton, L.J., Liu, L., Ouellet-Hellstrom, R., Patkar, N.M., Solomon, D.H., Lewis, J.D., Xie, F., Saag, K.G., Curtis, J.R. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306, 2331–2339.
   PubMed Web of Science ®Google Scholar
• Lee, J.H., Slifman, N.R., Gershon, S.K., Edwards, E.T., Schwieterman, W.D., Siegel, J.N., Wise, R.P., Brown, S.L., Udall, J.N. Jr, Braun, M.M. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002, 46, 2565–2570.
   PubMed Web of Science ®Google Scholar
• Slifman, N.R., Gershon, S.K., Lee, J.H., Edwards, E.T., Braun, M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum 2003, 48, 319–324.
   PubMed Web of Science ®Google Scholar
• Wallis, R.S., Broder, M., Wong, J., Lee, A., Hoq, L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005, 41 Suppl 3, S194–S198.
   Google Scholar
• Salmon-Ceron, D., Tubach, F., Lortholary, O., Chosidow, O., Bretagne, S., Nicolas, N., Cuillerier, E., Fautrel, B., Michelet, C., Morel, J., Puéchal, X., Wendling, D., Lemann, M., Ravaud, P., Mariette, X.; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70, 616–623.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq, J.A., Al-Khatti, A.A. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis 2010, 14, e153–e157.
   Google Scholar
• Eisendle, K., Fritsch, P. Fatal fulminant legionnaires’ disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy. Br J Dermatol 2005, 152, 585–586.
   PubMedGoogle Scholar
• Kamili, Q.A., Menter, A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 2010, 9, 57–60.
   PubMed Web of Science ®Google Scholar
• Kelesidis, T., Salhotra, A., Fleisher, J., Uslan, D.Z. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 2010, 60, 386–396.
   PubMed Web of Science ®Google Scholar
• Sri, J.C., Tsai, C.L., Deng, A., Gaspari, A.A. Osteomyelitis occurring during infliximab treatment of severe psoriasis. J Drugs Dermatol 2007, 6, 207–210.
   PubMedGoogle Scholar
• Stewart, M.W., Alvarez, S., Ginsburg, W.W., Shetty, R., McLain, W.C., Sleater, J.P. Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm 2006, 14, 181–183.
   PubMed Web of Science ®Google Scholar
• Dixon, W.G., Hyrich, K.L., Watson, K.D., Lunt, M., Galloway, J., Ustianowski, A., Symmons, D.P.; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69, 522–528.
   PubMed Web of Science ®Google Scholar
• Harris, J., Keane, J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010, 161, 1–9.
   PubMed Web of Science ®Google Scholar
• Mohan, V.P., Scanga, C.A., Yu, K., Scott, H.M., Tanaka, K.E., Tsang, E., Tsai, M.M., Flynn, J.L., Chan, J. Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69, 1847–1855.
   PubMed Web of Science ®Google Scholar
• Wallis, R.S., Broder, M.S., Wong, J.Y., Hanson, M.E., Beenhouwer, D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38, 1261–1265.
   PubMed Web of Science ®Google Scholar
• Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Cöster, L., Geborek, P., Jacobsson, L.T., Lindblad, S., Lysholm, J., Rantapää-Dahlqvist, S., Saxne, T., Romanus, V., Klareskog, L., Feltelius, N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52, 1986–1992.
   PubMed Web of Science ®Google Scholar
• Huo, R., Romanelli, P. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol 2010, 11 Suppl 1, 39–40.
   PubMedGoogle Scholar
• Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot-Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R.M., Bretagne, S., Emilie, D., Lemann, M., Lortholary, O., Lorthololary, O., Mariette, X.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60, 1884–1894.
   PubMed Web of Science ®Google Scholar
• Bruns, H., Meinken, C., Schauenberg, P., Härter, G., Kern, P., Modlin, R.L., Antoni, C., Stenger, S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119, 1167–1177.
   PubMed Web of Science ®Google Scholar
• Mariette, X. Lymphoma, rheumatoid arthritis, and TNF α antagonists. Joint Bone Spine 2010, 77, 195–197.
   PubMed Web of Science ®Google Scholar
• Haider, A.S., Cardinale, I.R., Whynot, J.A., Krueger, J.G. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007, 12, 9–15.
   PubMedGoogle Scholar
• Wallis, R.S. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007, 12, 16–21.
   PubMed Web of Science ®Google Scholar
• Saad, A.A., Ashcroft, D.M., Watson, K.D., Symmons, D.P., Noyce, P.R., Hyrich, K.L.; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49, 697–705.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guide for primary health care providers: targeted tuberculin testing and treatment of latent tuberculosis infection [online]. 2008 [cited 2010 September 3]; Available from: www.cdc.gov/tb/pubs/LTBI/pdf/TargetedLTBI05.pdf.
   Google Scholar
• Koike, R., Takeuchi, T., Eguchi, K., Miyasaka, N.; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17, 451–458.
   PubMedGoogle Scholar
• Perlmutter, A., Mittal, A., Menter, A. Tuberculosis and tumour necrosis factor- α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009, 160, 8–15.
   PubMedGoogle Scholar
• Nelson, D.R., Lim, H.L., Marousis, C.G., Fang, J.W., Davis, G.L., Shen, L., Urdea, M.S., Kolberg, J.A., Lau, J.Y. Activation of tumor necrosis factor- α system in chronic hepatitis C virus infection. Dig Dis Sci 1997, 42, 2487–2494.
   PubMed Web of Science ®Google Scholar
• Peterson, J.R., Hsu, F.C., Simkin, P.A., Wener, M.H. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62, 1078–1082.
   PubMed Web of Science ®Google Scholar
• Zein, N.N.; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42, 315–322.
   PubMed Web of Science ®Google Scholar
• Frankel, A.J., Van Voorhees, A.S., Hsu, S., Korman, N.J., Lebwohl, M.G., Bebo, B.F. Jr, Gottlieb, A.B.; National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009, 61, 1044–1055.
   PubMed Web of Science ®Google Scholar
• De Simone, C., Paradisi, A., Capizzi, R., Carbone, A., Siciliano, M., Amerio, P.L. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006, 54, 1102–1104.
   PubMed Web of Science ®Google Scholar
• Gandhi, R.K., Pickup, T., Sheth, P.B. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010, 146, 1151–1152.
   PubMed Web of Science ®Google Scholar
• Benucci, M., Manfredi, M., Mecocci, L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008, 14, 245–246.
   PubMed Web of Science ®Google Scholar
• Cansu, D.U., Kalifoglu, T., Korkmaz, C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008, 35, 421–424.
   PubMed Web of Science ®Google Scholar
• Montiel, P.M., Solis, J.A., Chirinos, J.A., a Casis, B., Sánchez, F., Rodríguez, S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008, 28, 718–720.
   PubMed Web of Science ®Google Scholar
• Sakellariou, G.T., Chatzigiannis, I. Long-term anti-TNF α therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007, 26, 950–952.
   PubMed Web of Science ®Google Scholar
• Fotiadou, C., Lazaridou, E., Ioannides, D. Safety of anti-tumour necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011, 25, 471–474.
   PubMed Web of Science ®Google Scholar
• Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., Zink, A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF- α agents. JAMA 2009, 301, 737–744.
   PubMed Web of Science ®Google Scholar
• Perez-Zafrilla, B., Garcia Doval, I., Carmona, L.. Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort [abstract no. FRI0129]. Ann Rheum Dis 2008;67:327.
   Google Scholar
• Kling, M.C., Larian, A.A., Scordi-Bello, I., Emer, J., Lebwohl, M.G. Fatal influenza A (H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. Arch Dermatol 2010, 146, 651–654.
   PubMedGoogle Scholar
• Petersen, B., Lorentzen, H. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab. Acta Derm Venereol 2008, 88, 523–524.
   PubMedGoogle Scholar
• Messina, M., Scichilone, N., Guddo, F., Bellia, V. Rapidly progressive organising pneumonia associated with cytomegalovirus infection in a patient with psoriasis. Monaldi Arch Chest Dis 2007, 67, 165–168.
   PubMedGoogle Scholar
• Berger, J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010, 33, 969–983.
   PubMed Web of Science ®Google Scholar
• Menon, K., Van Voorhees, A.S., Bebo, B.F., Gladman, D.D., Hsu, S., Kalb, R.E., Lebwohl, M.G., Strober, B.E.; National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010, 62, 291–299.
   PubMed Web of Science ®Google Scholar
• Cepeda, E.J., Williams, F.M., Ishimori, M.L., Weisman, M.H., Reveille, J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008, 67, 710–712.
   PubMed Web of Science ®Google Scholar
• Linardaki, G., Katsarou, O., Ioannidou, P., Karafoulidou, A., Boki, K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007, 34, 1353–1355.
   PubMed Web of Science ®Google Scholar
• Mikhail, M., Weinberg, J.M., Smith, B.L. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008, 144, 453–456.
   PubMedGoogle Scholar
• Tsiodras, S., Samonis, G., Boumpas, D.T., Kontoyiannis, D.P. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin Proc 2008, 83, 181–194.
   PubMed Web of Science ®Google Scholar
• Adams, A.E., Zwicker, J., Curiel, C., Kadin, M.E., Falchuk, K.R., Drews, R., Kupper, T.S. Aggressive cutaneous T-cell lymphomas after TNF α blockade. J Am Acad Dermatol 2004, 51, 660–662.
   PubMed Web of Science ®Google Scholar
• Berthelot, C., Cather, J., Jones, D., Duvic, M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006, 6, 329–332.
   PubMedGoogle Scholar
• Brown, S.L., Greene, M.H., Gershon, S.K., Edwards, E.T., Braun, M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46, 3151–3158.
   PubMed Web of Science ®Google Scholar
• Mahé, E., Descamps, V., Grossin, M., Fraitag, S., Crickx, B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003, 149, 170–173.
   PubMedGoogle Scholar
• Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295, 2275–2285.
   PubMed Web of Science ®Google Scholar
• Dziadzio, M., Smith, R. Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol 2007, 26, 1134–1135.
   PubMedGoogle Scholar
• Askling, J., Baecklund, E., Granath, F., Geborek, P., Fored, M., Backlin, C., Bertilsson, L., Cöster, L., Jacobsson, L.T., Lindblad, S., Lysholm, J., Rantapää-Dahlqvist, S., Saxne, T., van Vollenhoven, R., Klareskog, L., Feltelius, N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68, 648–653.
   PubMed Web of Science ®Google Scholar
• Wolfe, F., Michaud, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56, 2886–2895.
   PubMed Web of Science ®Google Scholar
• Watson, K., Dixon, W., Hyrich, K.L., Lunt, M. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR) [abstract no. OP25]. Rheumatology (Oxford) 2006;45:i10.
   PubMedGoogle Scholar
• Comte, C., Guilhou, J.J., Guillot, B., Dereure, O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology (Basel) 2008, 217, 284–285.
   PubMedGoogle Scholar
• Gelfand, J.M., Berlin, J., Van Voorhees, A., Margolis, D.J. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003, 139, 1425–1429.
   PubMed Web of Science ®Google Scholar
• Gelfand, J.M., Shin, D.B., Neimann, A.L., Wang, X., Margolis, D.J., Troxel, A.B. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006, 126, 2194–2201.
   PubMed Web of Science ®Google Scholar
• Ganguly, S. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. Am J Clin Dermatol 2009, 10, 125–126.
   PubMed Web of Science ®Google Scholar
• Chong, B.F., Wong, H.K. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin Exp Dermatol 2009, 34, e11–e13.
   Google Scholar
• Mariette, X., Tubach, F., Bagheri, H., Bardet, M., Berthelot, J.M., Gaudin, P., Heresbach, D., Martin, A., Schaeverbeke, T., Salmon, D., Lemann, M., Hermine, O., Raphael, M., Ravaud, P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69, 400–408.
   PubMed Web of Science ®Google Scholar
• Karampetsou, M.P., Liossis, S.N., Sfikakis, P.P. TNF-a antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010, 103, 917–928.
   PubMed Web of Science ®Google Scholar
• Atzeni, F., Turiel, M., Caporali, R., Cavagna, L., Tomasoni, L., Sitia, S., Sarzi-Puttini, P. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010, 9, 835–839.
   PubMed Web of Science ®Google Scholar
• Ryan, C., Leonardi, C.L., Krueger, J.G., Kimball, A.B., Strober, B.E., Gordon, K.B., Langley, R.G., de Lemos, J.A., Daoud, Y., Blankenship, D., Kazi, S., Kaplan, D.H., Friedewald, V.E., Menter, A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011, 306, 864–871.
   PubMedGoogle Scholar
• Tristano, A.G. Neurological adverse events associated with anti-tumor necrosis factor a treatment. J Neurol 2010, 257, 1421–1431.
   PubMed Web of Science ®Google Scholar
• Lozeron, P., Denier, C., Lacroix, C., Adams, D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α-blocker therapy. Arch Neurol 2009, 66, 490–497.
   PubMed Web of Science ®Google Scholar
• Mohan, N., Edwards, E.T., Cupps, T.R., Oliverio, P.J., Sandberg, G., Crayton, H., Richert, J.R., Siegel, J.N. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001, 44, 2862–2869.
   PubMed Web of Science ®Google Scholar
• Robinson, W.H., Genovese, M.C., Moreland, L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44, 1977–1983.
   PubMed Web of Science ®Google Scholar
• Sicotte, N.L., Voskuhl, R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57, 1885–1888.
   PubMed Web of Science ®Google Scholar
• Winkelmann, A., Patejdl, R., Wagner, S., Benecke, R., Zettl, U.K. Cerebral MRI lesions and anti-tumor necrosis factor- α therapy. J Neurol 2008, 255 Suppl 6, 109–114.
   PubMedGoogle Scholar
• Chan, J.W., Castellanos, A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010, 248, 283–287.
   PubMed Web of Science ®Google Scholar
• Chung, J.H., Van Stavern, G.P., Frohman, L.P., Turbin, R.E. Adalimumab-associated optic neuritis. J Neurol Sci 2006, 244, 133–136.
   PubMed Web of Science ®Google Scholar
• Giani, T., Simonini, G., Lunardi, C., Puccetti, A., De Martino, M., Falcini, F. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association? Clin Exp Rheumatol 2006, 24, 344–346.
   PubMedGoogle Scholar
• Alexopoulou, A., Koskinas, J., Soultati, A., Katsaounis, P., Kilidireas, K., Papageorgiou, C., Antoniou, C., Katsambas, A., Archimandritis, A. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol 2009, 28, 1337–1340.
   PubMed Web of Science ®Google Scholar
• Argyriou, A.A., Makridou, A., Karanasios, P., Makris, N. Axonal common peroneal nerve palsy and delayed proximal motor radial conduction block following infliximab treatment. J Pain Symptom Manage 2009, 38, e3–e5.
   PubMedGoogle Scholar
• Hanaoka, B.Y., Libecco, J., Rensel, M., Hajj-Ali, R.A. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol 2008, 35, 182.
   PubMed Web of Science ®Google Scholar
• Vedove, C.D., Del Giglio, M., Schena, D., Girolomoni, G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009, 301, 99–105.
   PubMedGoogle Scholar
• Pink, A.E., Fonia, A., Allen, M.H., Smith, C.H., Barker, J.N. Antinuclear antibodies associate with loss of response to antitumour necrosis factor- α therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010, 162, 780–785.
   PubMed Web of Science ®Google Scholar
• Abunasser, J., Forouhar, F.A., Metersky, M.L. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 2008, 134, 850–853.
   PubMedGoogle Scholar
• De Bandt, M., Sibilia, J., LeLoët, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J.L., Mariette, X.; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Arthritis Res Ther 2005, 7, R545–R551.
   PubMed Web of Science ®Google Scholar
• Exarchou, S.A., Voulgari, P.V., Markatseli, T.E., Zioga, A., Drosos, A.A. αImmune-mediated skin lesions in patients treated with anti-tumour necrosis factor inhibitors. Scand J Rheumatol 2009, 38, 328–331.
   PubMed Web of Science ®Google Scholar
• Farah, R.E., Shay, M.D. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 2007, 27, 1446–1448.
   PubMed Web of Science ®Google Scholar
• Izzi, S., Francesconi, F., Visca, P., Altieri, A., De Mutiis, C., Trevisan, G., Bonifati, C. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Dermatol Online J 2010, 16, 16.
   PubMedGoogle Scholar
• Klein, R., Rosenbach, M., Kim, E.J., Kim, B., Werth, V.P., Dunham, J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010, 146, 780–784.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.J., Khamashta, M.A. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86, 242–251.
   PubMed Web of Science ®Google Scholar
• Collamer, A.N., Battafarano, D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40, 233–240.
   PubMed Web of Science ®Google Scholar
• Ko, J.M., Gottlieb, A.B., Kerbleski, J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20, 100–108.
   PubMed Web of Science ®Google Scholar
• Reich, K., Nestle, F.O., Papp, K., Ortonne, J.P., Evans, R., Guzzo, C., Li, S., Dooley, L.T., Griffiths, C.E.; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366, 1367–1374.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Warning on hepatotoxicity with infliximab [online]. 2002 [cited 2010 September 4]; Available from: http://www.fda.gov/medwatch/SAFETY/2004/remicade_DHCP_dec04.pdf.
   Google Scholar
• García Aparicio, A.M., Rey, J.R., Sanz, A.H., Alvarez, J.S. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007, 26, 811–813.
   PubMed Web of Science ®Google Scholar
• Mancini, S., Amorotti, E., Vecchio, S., Ponz deLeon, M., Roncucci, L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010, 5, 193–200.
   PubMed Web of Science ®Google Scholar
• Massarotti, M., Marasini, B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 2009, 22, 547–549.
   PubMedGoogle Scholar
• Leak, A.M., Rincon-Aznar, B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 2008, 35, 2286–2287.
   PubMedGoogle Scholar
• Balato, N., Gallo, L., Gaudiello, F., Chiurazzi, F., Ayala, F. Transient and reversible thrombocytopenia in a psoriatic patient treated with etanercept. J Dermatolog Treat 2010, 21, 117–118.
   PubMed Web of Science ®Google Scholar
• Kuruvilla, J., Leitch, H.A., Vickars, L.M., Galbraith, P.F., Li, C.H., Al-Saab, S., Naiman, S.C. Aplastic anemia following administration of a tumor necrosis factor- α inhibitor. Eur J Haematol 2003, 71, 396–398.
   PubMed Web of Science ®Google Scholar
• Vidal, F., Fontova, R., Richart, C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003, 139, W–W63.
   PubMedGoogle Scholar
• Brunasso, A.M., Massone, C. Thrombocytopenia associated with the use of anti-tumor necrosis factor- α agents for psoriasis. J Am Acad Dermatol 2009, 60, 781–785.
   PubMed Web of Science ®Google Scholar
• Osting, V.C., Carter, J.D. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf 2010, 9, 421–429.
   PubMed Web of Science ®Google Scholar
• Berthelot, J.M., De Bandt, M., Goupille, P., Solau-Gervais, E., Lioté, F., Goeb, V., Azaïs, I., Martin, A., Pallot-Prades, B., Maugars, Y., Mariette, X.; CRI (Club Rhumatismes et Inflammation). Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009, 76, 28–34.
   PubMed Web of Science ®Google Scholar
• Puig, L., Barco, D., Alomar, A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology (Basel) 2010, 220, 71–76.
   PubMed Web of Science ®Google Scholar
• Moustou, A.E., Matekovits, A., Dessinioti, C., Antoniou, C., Sfikakis, P.P., Stratigos, A.J. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009, 61, 486–504.
   PubMed Web of Science ®Google Scholar
• Lecluse, L.L., Dowlatshahi, E.A., Limpens, C.E., de Rie, M.A., Bos, J.D., Spuls, P.I. Etanercept: an overview of dermatologic adverse events. Arch Dermatol 2011, 147, 79–94.
   PubMedGoogle Scholar
• Mortel, M.R., Emer, J. Prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol 2010, 9, 947–958.
   PubMedGoogle Scholar
• Rozenblit, M., Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009, 22, 56–60.
   PubMed Web of Science ®Google Scholar
• Kavanaugh, A., McInnes, I., Mease, P.J., editors.Golimumab, a new human TNF- α antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24 week efficacy and safety results of the randomized, placebo controlled GO-REVEAL study. European League Against Rheumatism; 2008 June 11–14; Paris.
   Google Scholar
• Girolomoni, G., Gisondi, P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol Venereol 2009, 23 Suppl 1, 3–8.
   PubMedGoogle Scholar